rs17651213 — MAPT Exon 3 Splice Regulator

Intronic MAPT variant that directly regulates tau exon 3 splicing via differential hnRNP F/Q binding; the G allele (H1 haplotype) reduces exon 3 inclusion, elevating 4-repeat tau isoforms and increasing risk for Parkinson's disease, PSP, and corticobasal degeneration

See your personal result for MAPT

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MAPT rs17651213 — The Splice Regulator at the Core of Tau Isoform Balance

Within the MAPT gene on chromosome 17, the rs17651213 variant sits in a functionally critical position: it is one of just two intronic polymorphisms that directly control how much tau protein includes its N-terminal exon 3 domain. While the broader H1/H2 haplotype distinction at MAPT has been recognized as a major neurodegenerative disease risk factor for decades, rs17651213 was identified in a landmark 2017 study as one of the molecular levers behind that risk — not merely a passive haplotype marker.

The MAPT gene produces tau, the microtubule-stabilizing protein whose aggregation into neurofibrillary tangles defines a family of neurodegenerative diseases called tauopathies. What makes tau biology especially complex is that the gene produces multiple isoforms through alternative splicing, and the balance between those isoforms — particularly the ratio of 3-repeat (3R) to 4-repeat (4R) tau — differs between healthy brains and diseased ones. The H1 haplotype, tagged by rs17651213's G allele, is consistently found in approximately 94% of progressive supranuclear palsy (PSP) patients compared to about 64% of the general population.

The Mechanism: hnRNP F/Q and Exon 3 Inclusion

A 2017 mechanistic study used whole-locus MAPT genomic DNA vectors to dissect the contribution of individual intronic variants to haplotype-specific tau splicing11 A 2017 mechanistic study used whole-locus MAPT genomic DNA vectors to dissect the contribution of individual intronic variants to haplotype-specific tau splicing
The study expressed H1 and H2 haplotypes with selective allele swaps at rs17651213 and rs1800547 to isolate each variant's contribution, then identified binding proteins by RNA-protein pull-down and mass spectrometry. The researchers identified that both rs17651213 and its partner rs1800547 create distinct RNA-protein binding patterns for two splicing factors: hnRNP F and hnRNP Q.

Crucially, when rs17651213 was swapped alone between haplotype backgrounds — placing the H2 (A) allele into an H1 context — exon 3 inclusion increased 2.52-fold. This makes rs17651213 the dominant driver of the two-SNP regulatory pair: it accounts for more of the exon 3 splicing difference between H1 and H2 than rs1800547 does individually. Overall, the H2 haplotype produces 1.76-fold more exon 3-containing tau transcripts than H1, and knockdown experiments confirmed that hnRNP F and hnRNP Q actively promote H1:H2 differential splicing — reducing both factors increased the H1:H2 exon 3 ratio, while the effects were allele-specific at rs17651213 and rs1800547.

Exon 3 encodes a region of tau's N-terminal projection domain involved in membrane interactions and cytoskeletal attachment. The H1-driven reduction in exon 3 inclusion shifts tau isoform composition toward higher 4-repeat (4R) forms, which are the main tau species in pathological aggregates in PSP and corticobasal degeneration (CBD). This mechanistic connection directly links the rs17651213 G allele to the molecular basis of 4R tauopathy susceptibility.

The Evidence for Parkinson's Disease and PSP

A large case-control study of 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes — defined using haplotype-tagging variants including rs17651213 — had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for Parkinson's disease22 A large case-control study of 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes — defined using haplotype-tagging variants including rs17651213 — had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for Parkinson's disease
The association was consistent across familial and sporadic disease, both sexes, and early- and late-onset subgroups. For PSP, a meta-analysis of 82 case-control studies found H1 haplotype carriers have an odds ratio of 1.96 for PSP and 2.51 for CBD33 a meta-analysis of 82 case-control studies found H1 haplotype carriers have an odds ratio of 1.96 for PSP and 2.51 for CBD
The most risk-elevated configurations are H1 sub-haplotypes H1d and H1g, which appear to compound the exon 3 splicing shift through additional cis-regulatory variants. H1/H1 homozygotes at rs17651213 are found in approximately 94% of neuropathologically confirmed PSP cases.

Alzheimer's Disease: A Tau-Driven Pathway

A study of 17,996 participants found the H1 haplotype independently associated with Alzheimer's disease risk (OR 1.12, p=0.0025), with the strongest effect in APOE ε4 non-carriers over age 7744 A study of 17,996 participants found the H1 haplotype independently associated with Alzheimer's disease risk (OR 1.12, p=0.0025), with the strongest effect in APOE ε4 non-carriers over age 77
This suggests that H1-driven tau isoform imbalance represents a distinct, slower causal pathway to AD that is less dependent on amyloid accumulation than the APOE ε4 pathway. For people without APOE ε4, the rs17651213 G/G genotype may be a more prominent contributor to late-life cognitive decline.

Practical Actions

The rs17651213 G/G genotype identifies the same population-level risk as H1/H1 status at rs1800547, since both SNPs co-define the H1 haplotype and are in very strong linkage disequilibrium. The key difference is that rs17651213 has been shown to be a functional driver — not just a tag — of the splicing difference. The actionable implications focus on neurological monitoring and neuroprotective lifestyle: awareness of early PSP/CBD features (distinct from typical Parkinson's disease) enables accurate diagnosis, and head trauma prevention is especially relevant given that TBI may accelerate tau pathology in H1/H1 individuals already producing tau isoforms skewed toward 4R-prone forms.

Interactions

rs17651213 and rs1800547 work as a mechanistic pair — both must be considered together to fully understand H1-versus-H2 exon 3 splicing differences. They are in very strong LD, so most H1/H1 individuals at rs17651213 will also be H1/H1 at rs1800547 and vice versa. The H1c sub-haplotype tagged by rs242557 adds further risk on top of the baseline H1 genotype. In Alzheimer's disease, the H1/H2 effect interacts with APOE genotype (rs429358), with H1 risk concentrated specifically in APOE ε4 non-carriers.

Genotype Interpretations

What each possible genotype means for this variant.

AG H1/H2 Heterozygote Intermediate

One H1 allele, one protective H2 allele — intermediate tauopathy risk with partial exon 3 splicing rescue

With one G (H1) and one A (H2) allele, your neurons produce MAPT transcripts from both haplotype backgrounds. The H2 allele at rs17651213 creates hnRNP F/Q binding patterns that favor exon 3 inclusion in a proportion of transcripts, partially shifting the 4R:3R tau balance compared to H1/H1. For PSP — the most strongly H1-associated disease — the H1/H2 genotype is found in roughly expected population proportions in case series, suggesting limited but not absent protection. For Parkinson's disease, a single H2 copy is estimated to reduce risk by roughly half the full H1/H1 effect compared to H2/H2.

GG H1/H1 Homozygote High Risk

Two copies of the H1 splicing variant — reduced exon 3 inclusion, elevated 4R tau, and higher risk for PSP, Parkinson's, and Alzheimer's disease

The molecular basis for GG risk lies in rs17651213's effect on MAPT exon 3 splicing. Swapping the H2 (A) allele into an H1 context at this position alone produces a 2.52-fold increase in exon 3 inclusion, making rs17651213 the stronger driver of the two-SNP (rs17651213 + rs1800547) regulatory pair. The G allele at rs17651213 creates binding patterns for splice factors hnRNP F and hnRNP Q that favor exon 3 exclusion — reducing production of tau isoforms that include the N2 insertion and shifting output toward 4R tau species.

Within the broader H1 background, sub-haplotypes carry different magnitudes of risk. H1g (OR 3.64 for PSP) and H1o (OR 2.60) represent high-risk H1 configurations, while the rs242557 A allele (H1c sub-haplotype) adds further risk on top of the GG baseline. For Alzheimer's disease, the H1-driven effect is strongest in APOE ε4 non-carriers over age 77, suggesting a tau-driven pathway to AD that is independent from amyloid-driven disease.

AA H2/H2 Homozygote Decreased

Two copies of the protective H2 splicing allele — enhanced exon 3 inclusion, lower 4R tau, and substantially reduced risk for most tauopathies

The A allele at rs17651213 creates hnRNP F/Q binding patterns that favor exon 3 inclusion in MAPT transcripts. With two A alleles, every MAPT transcript is produced under the H2 splicing program, maximizing exon 3 inclusion and producing a tau isoform profile enriched for N1-domain-containing tau and depleted of 4R-only forms. This is the molecular basis for H2/H2's protective effect against 4R tauopathies.

Despite protection against the most common tauopathies, H2/H2 status carries a paradoxical association with Pick's disease — a rare 3-repeat (3R) tauopathy. The inverse relationship supports the hypothesis that the H1/H2 distinction controls the 3R:4R tau balance: H2's higher 3R tau may increase susceptibility to 3R-predominant tauopathies while protecting against 4R forms. The rarity of H2 outside European populations (H2 allele frequency ~20% in Europeans but <2% in East Asians and Africans) suggests possible positive selection in European ancestral populations.